# IgA Nephropathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/iga-nephropathy

> 4 upcoming FDA catalysts in IgA Nephropathy: BHV-1400 (BHVN) on September 2028 (primary completion); BHV-1400 (BHVN) on Sep to Dec 2028 (topline data readout); JADE-001 (JBIO) on January 2029 (primary completion); JADE-001 (JBIO) on Jan to Apr 2029 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 19, 2025 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | IgA Nephropathy | completed | "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578834)) |
| Q2 2026 | [JADE-001 interim data readout](https://sec-api.dev/pdufa/jade101) | JBIO | IgA nephropathy | scheduled | "JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/d69373dex991.htm)) |
| November 4, 2026 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | IgA Nephropathy | completed | "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578834?tab=results)) |
| September 2028 | [BHV-1400 primary completion](https://sec-api.dev/pdufa/bhv-1400) | BHVN | IgA Nephropathy | scheduled | "NCT07642050 (A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07642050)) |
| Sep to Dec 2028 | [BHV-1400 topline data readout](https://sec-api.dev/pdufa/bhv-1400) | BHVN | IgA Nephropathy | scheduled | "NCT07642050 (A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07642050)) |
| January 2029 | [JADE-001 primary completion](https://sec-api.dev/pdufa/jade101) | JBIO | IgA Nephropathy | scheduled | "NCT07541287 (A Study of JADE101 in Participants With Immunoglobulin A Nephropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Jade Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07541287)) |
| Jan to Apr 2029 | [JADE-001 topline data readout](https://sec-api.dev/pdufa/jade101) | JBIO | IgA Nephropathy | scheduled | "NCT07541287 (A Study of JADE101 in Participants With Immunoglobulin A Nephropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Jade Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07541287)) |

## Drugs

- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [JADE-001](https://sec-api.dev/pdufa/jade101) (JBIO)
- [BHV-1400](https://sec-api.dev/pdufa/bhv-1400) (BHVN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/iga-nephropathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IgA Nephropathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/iga-nephropathy

```bibtex
@misc{secapidev_indications_iga_nephropathy_20261116,
  title        = {IgA Nephropathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/iga-nephropathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_iga_nephropathy_20261116","title":"IgA Nephropathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/iga-nephropathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
